Formulary Search Results for: CALCIUM AND VITAMIN D
10.2.2 Skeletal muscle relaxants - View Category
Restrictions:
Restricted to specialist use for treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
Prescribing Notes:
Patients commencing treatment should be reviewed via a formal assessment conducted by the specialist service at 4 weeks. Treatment should be discontinued at that point if a clinically significant improvement is not seen. Patients should also continue to be reviewed regularly thereafter to ensure continuing benefit.
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for:
- Monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.
- In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
Prescribing Notes:
Non-formulary indications that have not been recommended by SMC for use in NHS Scotland:
- In combination with platinum-containing chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.
7.5.4 Selective kappa opioid receptor agonist - View Category
Restrictions:
Treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. Restricted to in-centre haemodialysis use only, in patients with an inadequate response to best supportive care for reducing itch.
8.1.5 Other antineoplastic drugs - View Category
Restrictions:
Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following indication:
- Non-metastatic castration-resistant prostate cancer (nmCRPC) in men who are at high risk of developing metastatic disease.
- Treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
Prescribing Notes:
The following indication is not recommended by SMC and is non-Formulary:
- Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy [SMC non-submission].
11.4.1 Eye-corticosteroids - View Category
11.4.1 Eye-corticosteroids - View Category
Prescribing Notes:
Prevention and treatment of inflammation, and prevention of infection associated with cataract surgery in adults.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
11.6.1 Beta - blockers - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
Preservative-containing eye drops are the first choice preparation.
Some preparations can provide intraocular pressure reduction for up to 24 hours; however, these should be reserved only for patients with compliance issues.
11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment - View Category
11.4.1 Eye-corticosteroids - View Category
Restrictions:
Macular Oedema: Restricted to specialist use in adult patients with macular oedema following central retinal vein occlusion (CRVO) and in patients with branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with dense macular haemorrhage or patients who have received and failed on previous laser treatment in accordance with local protocol.
Diabetic Macular Oedema: Use in the treatment of adults with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy, is restricted to specialist use only.
Non-infectious Uveitis: Use for the treatment of non-infectious uveitis is restricted to specialist use in accordance with NICE TA460.
NHSGGC Protocols for the Formulary indications can be accessed here.
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to use on the advice of local microbiologists and infectious disease specialists only in the following situations:
- in accordance with OPAT service clinical management pathway for second-line use or when meticillin-resistant Staphylococcus aureus (MRSA) infection is suspected AND when the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment.
Prescribing Notes:
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.